{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T11:59:35Z","timestamp":1791115175731,"version":"4.1.0"},"reference-count":34,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2007,4,26]],"date-time":"2007-04-26T00:00:00Z","timestamp":1177545600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Hematological Oncology"],"published-print":{"date-parts":[[2007,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Thrombotic and haemorrhagic complications are the main causes of morbidity in Essential Thrombocythemia (ET). We investigated the clinical and laboratory characteristics associated with the occurrence of these events with the aim of identifying subgroups of patients who might benefit from anti\u2010aggregant and\/or cytoreductive therapy. The study involved 306 consecutive ET patients (median age 58 years and median follow\u2010up 96 months); the investigated variables were age, gender, platelet count, previous history of thrombotic or haemorrhagic events, disease duration and cardiovascular risk factors. Forty\u2010six patients (15%) experienced thrombotic complications during the follow\u2010up: 26\/64 patients with a previous history of thrombosis (40.6%) and 20\/242 patients without (8.3%; <jats:italic>p<\/jats:italic>\u2009&lt;\u20090.0001). Thirty\u2010one patients (10%) experienced major haemorrhagic complications, mainly gastrointestinal tract bleeding: 3 with and 28 without a history of haemorrhagic events (<jats:italic>p<\/jats:italic>\u2009=\u20090.052). When the patients with a negative history of thrombosis were stratified on the basis of the number of cardiovascular risk factors (none vs. one vs. more than one), there was a significant correlation with the occurrence of thrombotic events (<jats:italic>p<\/jats:italic>\u2009&lt;\u20090.05). ET patients with a positive history of thrombosis are at high risk of thrombotic complications, and should receive cytoreductive and anti\u2010aggregant treatment. Asymptomatic patients with a negative thrombotic history and no cardiovascular risk factors are at low risk, and should not be treated. Patients with a negative thrombotic history and one or more cardiovascular risk factors are at intermediate risk, and should be treated with anti\u2010aggregant and\/or cytoreductive therapy. The need for treatment should be periodically re\u2010evaluated. Age and platelet count, generally accepted as very important risk factors for thrombosis, did not seem in our series associated with an increased risk for thrombosis. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/hon.816","type":"journal-article","created":{"date-parts":[[2007,4,26]],"date-time":"2007-04-26T13:17:54Z","timestamp":1177593474000},"page":"115-120","source":"Crossref","is-referenced-by-count":31,"title":["Analysis of risk factors predicting thrombotic and\/or haemorrhagic complications in 306 patients with Essential Thrombocythemia"],"prefix":"10.1002","volume":"25","author":[{"given":"Franca","family":"Radaelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariangela","family":"Colombi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rossella","family":"Calori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vittorio Ruggero","family":"Zilioli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefania","family":"Bramanti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Iurlo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Zanella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2007,4,26]]},"reference":[{"key":"e_1_2_1_2_2","first-page":"177","article-title":"Essential Thrombocythemia: an interim report from the Polycythemia Vera Study Group","volume":"23","author":"Murphy S","year":"1986","journal-title":"Semin Hematol"},{"key":"e_1_2_1_3_2","first-page":"29","article-title":"Experience of the Polycythemia Vera Study Group with Essential Thrombocythemia: a final report on diagnostic criteria, survival and leukemic transition by treatment","volume":"34","author":"Murphy S","year":"1997","journal-title":"Semin Hematol"},{"key":"e_1_2_1_4_2","first-page":"1541","volume-title":"Williams Hematology","author":"Schafer AI","year":"2001"},{"key":"e_1_2_1_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra035363"},{"key":"e_1_2_1_6_2","first-page":"1277","volume-title":"Hematology: Basic Principles and Practice","author":"Fruchtman SM","year":"2005"},{"key":"e_1_2_1_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2005.05543.x"},{"key":"e_1_2_1_8_2","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1990.8.3.556"},{"key":"e_1_2_1_9_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199504273321704"},{"key":"e_1_2_1_10_2","first-page":"215","article-title":"Practice guidelines for the therapy of Essential Thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for the Bone Marrow Transplantation","volume":"89","author":"Barbui T","year":"2004","journal-title":"Haematologica"},{"key":"e_1_2_1_11_2","doi-asserted-by":"publisher","DOI":"10.4065\/76.1.22"},{"key":"e_1_2_1_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2004.06.032"},{"key":"e_1_2_1_13_2","doi-asserted-by":"publisher","DOI":"10.1007\/s002770050555"},{"key":"e_1_2_1_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8652(199905)61:1<10::AID-AJH3>3.0.CO;2-I"},{"key":"e_1_2_1_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910515)67:10<2658::AID-CNCR2820671042>3.0.CO;2-C"},{"key":"e_1_2_1_16_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2000.90236.x"},{"key":"e_1_2_1_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910601)67:11<2926::AID-CNCR2820671136>3.0.CO;2-3"},{"key":"e_1_2_1_18_2","volume-title":"Pathology and genetics of haematopoietic and lymphoid tissues. World Health Organization Classification of Tumors","author":"Imbert M","year":"2001"},{"key":"e_1_2_1_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05277.x"},{"key":"e_1_2_1_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.2000.02188.x"},{"key":"e_1_2_1_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.0007-1048.2002.03367.x"},{"key":"e_1_2_1_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0369-8114(00)00026-2"},{"key":"e_1_2_1_23_2","doi-asserted-by":"publisher","DOI":"10.4065\/81.2.159"},{"key":"e_1_2_1_24_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-09-046342"},{"key":"e_1_2_1_25_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1998.01021.x"},{"key":"e_1_2_1_26_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2141.1997.d01-2127.x"},{"key":"e_1_2_1_27_2","doi-asserted-by":"publisher","DOI":"10.1177\/107602969900500210"},{"key":"e_1_2_1_28_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00282-997-0011-x"},{"key":"e_1_2_1_29_2","doi-asserted-by":"crossref","first-page":"3589","DOI":"10.1182\/blood.V95.11.3589","article-title":"Acquired DNA mutations associated with in vivo hydroxyrurea exposure","volume":"95","author":"Hanft VN","year":"2000","journal-title":"Blood"},{"key":"e_1_2_1_30_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2004.02.006"},{"key":"e_1_2_1_31_2","doi-asserted-by":"publisher","DOI":"10.1034\/j.1600-0609.2002.02734.x"},{"key":"e_1_2_1_32_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-9343(87)90696-6"},{"key":"e_1_2_1_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19900801)66:3<549::AID-CNCR2820660324>3.0.CO;2-6"},{"key":"e_1_2_1_34_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V91.2.616"},{"key":"e_1_2_1_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0369-8114(00)00024-9"}],"container-title":["Hematological Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhon.816","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hon.816","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T08:11:47Z","timestamp":1700035907000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hon.816"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,4,26]]},"references-count":34,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2007,9]]}},"alternative-id":["10.1002\/hon.816"],"URL":"https:\/\/doi.org\/10.1002\/hon.816","archive":["Portico"],"relation":{},"ISSN":["0278-0232","1099-1069"],"issn-type":[{"value":"0278-0232","type":"print"},{"value":"1099-1069","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,4,26]]}}}